What question did this study set out to answer?

To assess the real-world efficacy and safety of dalpiciclib in hormone receptor-positive advanced breast cancer patients.

March 25, 2026CancersOpen Access

Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study

View Full Paper

Ask AI

Bookmark

To assess the real-world efficacy and safety of dalpiciclib in hormone receptor-positive advanced breast cancer patients.
Conducted a two-center, retrospective cohort study
Analyzed data from 76 patients treated with dalpiciclib
Collected data on progression-free survival and adverse events
Utilized Kaplan–Meier estimates for statistical analysis
Median progression-free survival was 12.00 months
First-line therapy patients had improved mPFS of 17.00 months
Prior exposure to CDK4/6 inhibitors linked to poorer outcomes
Most common adverse events were grade 1–2 hematologic toxicities

No takes yet. Share an insight, caveat, or question.

Retrospective study evaluates dalpiciclib outcomes in advanced breast cancer patients, suggesting efficacy with early therapy.

Li et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark